Two compounds, one target: energy
SuperRUSH is not a stimulant and it does not work like one. Both actives in the vial aim at the same thing from opposite ends of the same problem: 5-Amino-1MQ protects the fuel your cells run on, and MOTS-c increases the machinery that burns it. One stops waste. The other builds capacity.
The effect users describe is not a lift or a rush despite the name — it is the absence of the drop. Not fighting sleep after lunch. Not fading on a long drive. Energy that is there because the underlying supply was not being squandered, rather than borrowed against and repaid later.
Stimulants borrow energy. This is about not losing it in the first place.
Caffeine and its relatives work by blocking the signal that tells you that you are tired. Nothing about the cell's actual energy situation changes — you simply stop hearing about it, and the bill arrives later. The two compounds here operate a layer below that, on the supply itself.
An enzyme called NNMT continuously consumes NAD+ precursors and methyl donors to produce a metabolic dead-end product. Research describes NNMT as elevated in aged adipose tissue and obese skeletal muscle. Inhibit it and those pools stay where they are useful.
A peptide your own mitochondria produce, described in research as an exercise signal — activating AMPK and PGC-1α, the pathway associated with mitochondrial biogenesis. Restoring supply is worth little if there is nothing additional to spend it on.
The two are mechanistically complementary rather than additive. That is the entire rationale for combining them, and it is why this exists as a blend rather than as two products sold beside each other.
One week per vial, seven doses
| Active | Per vial | Per dose | Role |
|---|---|---|---|
| 5-Amino-1MQ (chloride salt) | 150 mg | ~21 mg | NNMT inhibitor — protects the NAD+ and methyl-donor supply |
| MOTS-c | 10 mg | ~1.43 mg | Mitochondrial-derived peptide — AMPK/PGC-1α, builds capacity |
Reconstitute once, dose seven times across seven days. The weekly vial is deliberate: it is short enough that the solution is used well inside its stable window, and long enough that you are not reconstituting every other day.
5-Amino-1MQ — closing the drain
NAD+ is the cofactor almost every energy-producing reaction in the cell depends on, and the body is constantly recycling it. Nicotinamide N-methyltransferase — NNMT — sits in that recycling loop and diverts from it. Research describes NNMT as taking nicotinamide, a recyclable NAD+ precursor, and methylating it into 1-methylnicotinamide, which is excreted. Two resources go out at once: the NAD+ precursor that could have been salvaged, and the methyl group spent doing it.
The reason this matters more with age and weight is that the enzyme is not constant. Research describes NNMT as elevated in aged adipose tissue and in obese skeletal muscle — so the people with the least metabolic headroom are described as running the largest version of the leak.
5-Amino-1MQ is a small-molecule NNMT inhibitor. Published work by Neelakantan and colleagues reported that methylquinolinium inhibitors of this class were membrane permeable and relatively selective, reduced intracellular 1-methylnicotinamide, and raised intracellular NAD+ and SAM. In adipocytes, concentrations of 30 µM and 60 µM were reported to reduce lipogenesis by 50% and 70% respectively against untreated controls. Preclinical models describe an increase in whole-body metabolic rate.
We formulate 5-Amino-1MQ as the chloride salt, never the iodide. This is a genuine safety distinction rather than a preference: an iodide salt delivers an iodide load with every dose, and a large acute iodide load is associated in the literature with the Wolff-Chaikoff effect — transient suppression of thyroid hormone synthesis. On a daily compound aimed at metabolism, quietly suppressing the thyroid would be an unusually counterproductive side effect. Iodide salt is cheaper and easier to source. We do not use it.
The honest limit: research on 5-Amino-1MQ is preclinical. As of early 2026 there are no published human clinical trials. The mechanism is clean and the cell and animal data are consistent, but anyone telling you the human effect size is established is ahead of the evidence.
MOTS-c — a signal your mitochondria write themselves
MOTS-c is unusual among peptides in where it comes from. It is a 16-amino-acid peptide encoded not in nuclear DNA but within the mitochondrial genome itself — in the short open reading frame of the 12S rRNA gene. The mitochondria are, in effect, writing a message to the rest of the cell.
The message is about energy stress. Research describes MOTS-c expression as rising in response to stress and exercise, and describes the peptide translocating to the nucleus where it regulates stress-adaptation genes carrying antioxidant response elements. Its primary described route is the folate–AICAR–AMPK pathway — AMPK being the switch cells throw when they need to stop storing and start burning.
This is why it gets called an exercise mimetic in the literature. Not because it replaces training, but because it is one of the signals training produces. Published work reports MOTS-c administration enhancing muscle mitochondrial bioenergetic performance in a manner dependent on both PGC-1α and AMPK — the same transcriptional machinery associated with building additional mitochondrial capacity. Reported metabolic effects include enhanced glucose uptake, increased fat oxidation and improved insulin sensitivity.
The honest limit here too: human evidence is early and mixed. Associations with insulin sensitivity appear context-dependent, and circulating MOTS-c levels do not map cleanly onto better metabolic health across all studies. The mechanistic and preclinical case is strong; the human case is still being built.
MOTS-c is the fragile one, and it sets the rules
By mass this vial is overwhelmingly 5-Amino-1MQ — 150 mg against 10 mg. But the formulation is designed around the 10 mg, because MOTS-c is the component that can be lost.
Its 16-residue sequence carries three oxidation-sensitive residues — two methionines and a tryptophan. Methionine and tryptophan are among the residues the literature identifies as most readily oxidised on contact with oxygen, and having three of them in a short peptide means there is very little margin. It is also light-sensitive.
This is precisely the case the argon system was built for. A peptide with three oxidation targets in sixteen residues, sitting in a vial for a week after reconstitution, is not a molecule you leave under room air and hope. Inert headspace here is not a marketing flourish — it is the difference between the seventh dose and the first containing the same thing.
The rest follows from that. A lyoprotectant sugar at a 3:1 ratio to the peptide preserves its structure through freeze-drying, with a crystalline scaffold providing cake structure at a high total solid load. The vehicle is buffered, and pH is checked after the 5-Amino-1MQ dissolves rather than assumed — because it is a hydrochloride salt, and 150 mg of it will pull the solution acidic if nothing is holding the line.
At roughly 646 mOsm/kg this is a hypertonic solution — about 2.3 times plasma — and we would rather publish that than leave it off. The cause is arithmetic rather than carelessness: 150 mg of a dissociating chloride salt in 3.5 mL contributes around 440 mOsm/kg on its own, before any excipient exists. Any formulation delivering 21 mg of this compound per dose in a reasonable injection volume lands in the same place. Sting at the injection site is the expected trade for a dose that size.
What people actually report
The most consistent report is not a stimulant effect. It is steadiness — energy that does not arrive as a peak and does not leave as a crash, and specifically the disappearance of the afternoon and long-drive drowsiness that people had stopped treating as a symptom because it had always been there.
The second report, and the one with less literature behind it, concerns stalling. On a GLP-1 protocol progress plateaus, and this is the compound users most often credit with moving through it. There is a mechanistic story available — restoring NAD+ and methyl-donor pools while signalling for additional mitochondrial capacity is a plausible route out of a metabolic plateau — but we will label it what it is: a mechanism that fits the observation, not a demonstrated cause.
One compound stops the waste. The other increases what there is to spend. Neither is a stimulant, and neither is borrowing against tomorrow.
All custom blends